VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q104696520  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000106.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q104696520‏
035 ‎‡a  (OCoLC)Q104696520‏
100 0 ‎‡a  Mark Wansbrough-Jones‏ ‎‡9  en‏ ‎‡9  nl‏
670 ‎‡a  Author's Buruli ulcer‏
670 ‎‡a  Author's Buruli ulcer disease: prospects for a vaccine‏
670 ‎‡a  Author's Buruli ulcer: emerging from obscurity.‏
670 ‎‡a  Author's Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.‏
670 ‎‡a  Author's Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease.‏
670 ‎‡a  Author's Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease‏
670 ‎‡a  Author's Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial‏
670 ‎‡a  Author's Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana‏
670 ‎‡a  Author's High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana‏
670 ‎‡a  Author's IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with infection‏
670 ‎‡a  Author's Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease‏
670 ‎‡a  Author's Infection with Mansonella perstans Nematodes in Buruli Ulcer Patients, Ghana‏
670 ‎‡a  Author's Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease.‏
670 ‎‡a  Author's Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease‏
670 ‎‡a  Author's Mycobacterium ulcerans Disease: Buruli Ulcer‏
670 ‎‡a  Author's Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies‏
670 ‎‡a  Author's Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring‏
670 ‎‡a  Author's Neglected tropical diseases‏
670 ‎‡a  Author's Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice.‏
670 ‎‡a  Author's Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load‏
670 ‎‡a  Author's Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay‏
670 ‎‡a  Author's Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.‏
670 ‎‡a  Author's Reply to "compliance with antimicrobial therapy for buruli ulcer".‏
670 ‎‡a  Author's Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial‏
670 ‎‡a  Author's Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer Chromatography‏
670 ‎‡a  Author's Treatment of tuberculosis in HIV-infected individuals‏
919 ‎‡a  neglectedtropicaldiseases‏ ‎‡A  Neglected tropical diseases‏ ‎‡9  1‏
919 ‎‡a  mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring‏ ‎‡A  Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring‏ ‎‡9  1‏
919 ‎‡a  mycobacteriumulceransinfectionburuliorbairnsdaleulcerchallengesindevelopingmanagementstrategies‏ ‎‡A  Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies‏ ‎‡9  1‏
919 ‎‡a  mycobacteriumulceransdiseaseburuliulcer‏ ‎‡A  Mycobacterium ulcerans Disease: Buruli Ulcer‏ ‎‡9  1‏
919 ‎‡a  microbiologicalhistologicalimmunologicalandtoxinresponsetoantibiotictreatmentinthemousemodelofmycobacteriumulceransdisease‏ ‎‡A  Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease‏ ‎‡9  1‏
919 ‎‡a  metabolomicprofilesdelineatemycolactonesignatureinburuliulcerdisease‏ ‎‡A  Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease.‏ ‎‡9  1‏
919 ‎‡a  infectionwithmansonellaperstansnematodesinburuliulcerpatientsghana‏ ‎‡A  Infection with Mansonella perstans Nematodes in Buruli Ulcer Patients, Ghana‏ ‎‡9  1‏
919 ‎‡a  immunosuppressivesignatureofcutaneousmycobacteriumulceransinfectionintheperipheralbloodofpatientswithburuliulcerdisease‏ ‎‡A  Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease‏ ‎‡9  1‏
919 ‎‡a  ifnγandil5wholebloodresponsedirectedagainstmycolactonepolyketidesynthasedomainsinpatientswithinfection‏ ‎‡A  IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with infection‏ ‎‡9  1‏
919 ‎‡a  highprevalenceofmultidrugresistanttuberculosisamongpatientswithrifampicinresistanceusinggenexpertmycobacteriumtuberculosisrifampicininghana‏ ‎‡A  High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana‏ ‎‡9  1‏
919 ‎‡a  geneticdiversityofpcrpositiveculturenegativeandculturepositivemycobacteriumulceransisolatedfromburuliulcerpatientsinghana‏ ‎‡A  Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana‏ ‎‡9  1‏
919 ‎‡a  effectsofhydroxychloroquineonimmuneactivationanddiseaseprogressionamonghivinfectedpatientsnotreceivingantiretroviraltherapyarandomizedcontrolledtrial‏ ‎‡A  Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial‏ ‎‡9  1‏
919 ‎‡a  combinedinflammatoryandmetabolicdefectsreflectedbyreducedserumproteinlevelsinpatientswithburuliulcerdisease‏ ‎‡A  Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease‏ ‎‡9  1‏
919 ‎‡a  clinicalandbacteriologicalefficacyofrifampinstreptomycincombinationfor2weeksfollowedbyrifampinandclarithromycinfor6weeksfortreatmentofmycobacteriumulceransdisease‏ ‎‡A  Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease.‏ ‎‡9  1‏
919 ‎‡a  clearanceofviablemycobacteriumulceransfromburuliulcerlesionsduringantibiotictreatmentasdeterminedbycombined16srrnareversetranscriptaseis2404qpcrassay‏ ‎‡A  Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.‏ ‎‡9  1‏
919 ‎‡a  buruliulceremergingfromobscurity‏ ‎‡A  Buruli ulcer: emerging from obscurity.‏ ‎‡9  1‏
919 ‎‡a  buruliulcerdiseaseprospectsforavaccine‏ ‎‡A  Buruli ulcer disease: prospects for a vaccine‏ ‎‡9  1‏
919 ‎‡a  buruliulcer‏ ‎‡A  Buruli ulcer‏ ‎‡9  1‏
919 ‎‡a  rapiddetectionofmycobacteriumulceranswithisothermalrecombinasepolymeraseamplificationassay‏ ‎‡A  Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay‏ ‎‡9  1‏
919 ‎‡a  recentadvancesroleofmycolactoneinthepathogenesisandmonitoringofmycobacteriumulceransinfectionburuliulcerdisease‏ ‎‡A  Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.‏ ‎‡9  1‏
919 ‎‡a  replytocompliancewithantimicrobialtherapyforburuliulcer‏ ‎‡A  Reply to "compliance with antimicrobial therapy for buruli ulcer".‏ ‎‡9  1‏
919 ‎‡a  rifampicinandclarithromycinextendedreleaseversusrifampicinandstreptomycinforlimitedburuliulcerlesionsarandomisedopenlabelnoninferiorityphase3trial‏ ‎‡A  Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial‏ ‎‡9  1‏
919 ‎‡a  simplerapidmycobacteriumulceransdiseasediagnosisfromclinicalsamplesbyfluorescenceofmycolactoneonthinlayerchromatography‏ ‎‡A  Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer Chromatography‏ ‎‡9  1‏
919 ‎‡a  treatmentoftuberculosisinhivinfectedindividuals‏ ‎‡A  Treatment of tuberculosis in HIV-infected individuals‏ ‎‡9  1‏
919 ‎‡a  paradoxicalreactionsinburuliulcerafterinitiationofantibiotictherapyrelationshiptobacterialload‏ ‎‡A  Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load‏ ‎‡9  1‏
919 ‎‡a  oraltreatmentforpatientswithburuliulcercoinfectedwithhivthinktwice‏ ‎‡A  Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice.‏ ‎‡9  1‏
996 ‎‡2  NDL|001189898‏
996 ‎‡2  LNB|LNC10-000336712‏
996 ‎‡2  BIBSYS|9005710‏
996 ‎‡2  CAOONL|ncf10469015‏
996 ‎‡2  SUDOC|251135942‏
996 ‎‡2  BIBSYS|1488830535933‏
996 ‎‡2  LC|no2005008108‏
996 ‎‡2  SUDOC|082327068‏
996 ‎‡2  JPG|500232159‏
996 ‎‡2  J9U|987007457475805171‏
996 ‎‡2  BAV|495_349690‏
996 ‎‡2  ISNI|0000000077142665‏
996 ‎‡2  ISNI|0000000070920313‏
996 ‎‡2  LC|no2018015613‏
996 ‎‡2  LC|n 91002141‏
996 ‎‡2  J9U|987007339155505171‏
996 ‎‡2  NUKAT|n 2022200440‏
996 ‎‡2  LC|no2018067175‏
996 ‎‡2  NLA|000035567110‏
996 ‎‡2  LC|n 2015050789‏
996 ‎‡2  LC|no2010136459‏
996 ‎‡2  ISNI|0000000055596471‏
996 ‎‡2  LC|n 88621549‏
996 ‎‡2  DNB|171244230‏
996 ‎‡2  NLA|000035252773‏
996 ‎‡2  J9U|987007404549305171‏
996 ‎‡2  NKC|ola2013750150‏
996 ‎‡2  BNF|13474782‏
996 ‎‡2  ISNI|0000000054505857‏
996 ‎‡2  NTA|128495162‏
996 ‎‡2  DNB|1075549620‏
996 ‎‡2  CAOONL|ncf11194278‏
996 ‎‡2  ISNI|000000008405740X‏
996 ‎‡2  DNB|1268649287‏
996 ‎‡2  SZ|1067414789‏
996 ‎‡2  BNF|16577770‏
996 ‎‡2  ISNI|0000000083631764‏
996 ‎‡2  NUKAT|n 2019005349‏
996 ‎‡2  BNF|15700315‏
996 ‎‡2  BIBSYS|90059304‏
996 ‎‡2  DNB|174002270‏
996 ‎‡2  LC|n 88657896‏
996 ‎‡2  ISNI|0000000043392033‏
996 ‎‡2  RERO|A020140661‏
996 ‎‡2  RERO|A006436500‏
996 ‎‡2  SUDOC|236676415‏
996 ‎‡2  ISNI|0000000114674469‏
996 ‎‡2  BAV|495_349691‏
996 ‎‡2  J9U|987007456475905171‏
996 ‎‡2  LNB|LNC10-000092208‏
996 ‎‡2  BIBSYS|90777083‏
996 ‎‡2  NUKAT|n 98000614‏
996 ‎‡2  NII|DA11724068‏
996 ‎‡2  LC|n 2008053638‏
996 ‎‡2  DNB|10849344X‏
996 ‎‡2  CAOONL|ncf10644797‏
996 ‎‡2  NTA|370173511‏
996 ‎‡2  KRNLK|KAC200807186‏
996 ‎‡2  SUDOC|158185536‏
996 ‎‡2  DNB|1324107413‏
996 ‎‡2  ISNI|0000000115918277‏
996 ‎‡2  DNB|114183317‏
996 ‎‡2  NII|DA00373868‏
996 ‎‡2  NUKAT|n 2009141576‏
996 ‎‡2  LC|n 88009220‏
996 ‎‡2  PTBNP|156705‏
996 ‎‡2  NUKAT|n 2005002451‏
996 ‎‡2  LC|no2021082547‏
996 ‎‡2  LC|n 90605925‏
996 ‎‡2  ISNI|0000000037655175‏
996 ‎‡2  BNF|17148765‏
996 ‎‡2  BIBSYS|11078666‏
996 ‎‡2  BIBSYS|41830‏
996 ‎‡2  N6I|vtls000010735‏
996 ‎‡2  ISNI|0000000383176724‏
996 ‎‡2  BIBSYS|12028681‏
996 ‎‡2  NTA|07508256X‏
996 ‎‡2  ISNI|0000000035910080‏
996 ‎‡2  BAV|495_287887‏
996 ‎‡2  RERO|A009312185‏
996 ‎‡2  LC|nb 99116083‏
996 ‎‡2  LC|nb2021000830‏
996 ‎‡2  J9U|987007460945805171‏
996 ‎‡2  SUDOC|077315804‏
996 ‎‡2  ISNI|0000000101373034‏
996 ‎‡2  DNB|136030645‏
996 ‎‡2  LC|n 88639481‏
996 ‎‡2  ISNI|0000000080595200‏
996 ‎‡2  JPG|500018578‏
996 ‎‡2  LC|nb 99052660‏
996 ‎‡2  BIBSYS|90830440‏
996 ‎‡2  NII|DA07744389‏
996 ‎‡2  BIBSYS|90763725‏
996 ‎‡2  LC|n 88669220‏
996 ‎‡2  J9U|987007315964705171‏
996 ‎‡2  NII|DA17774604‏
996 ‎‡2  NDL|00738888‏
996 ‎‡2  LC|n 96034279‏
996 ‎‡2  LC|n 79058341‏
996 ‎‡2  SUDOC|201071452‏
996 ‎‡2  LC|n 2011080877‏
996 ‎‡2  B2Q|0000014377‏
996 ‎‡2  CAOONL|ncf10642195‏
996 ‎‡2  NII|DA10688548‏
996 ‎‡2  CAOONL|ncf12114972‏
996 ‎‡2  LC|no2019116314‏
996 ‎‡2  ISNI|0000000037293514‏
996 ‎‡2  DNB|1034964887‏
996 ‎‡2  LC|no2019098921‏
996 ‎‡2  LC|n 96054634‏
996 ‎‡2  ISNI|0000000424901823‏
996 ‎‡2  CAOONL|ncf11337428‏
996 ‎‡2  ISNI|0000000051460382‏
996 ‎‡2  ISNI|0000000063684287‏
996 ‎‡2  CAOONL|ncf10075177‏
996 ‎‡2  ISNI|0000000076841085‏
996 ‎‡2  LC|n 85080076‏
996 ‎‡2  LC|n 50007165‏
996 ‎‡2  ISNI|0000000463376240‏
996 ‎‡2  LC|n 2013004326‏
996 ‎‡2  NTA|32208895X‏
996 ‎‡2  NUKAT|n 2017196870‏
996 ‎‡2  NDL|01203015‏
996 ‎‡2  NTA|138257639‏
996 ‎‡2  NTA|269084975‏
996 ‎‡2  NTA|394186389‏
996 ‎‡2  BIBSYS|8022533‏
996 ‎‡2  NII|DA17079796‏
996 ‎‡2  ISNI|0000000043076911‏
996 ‎‡2  DNB|1344166563‏
996 ‎‡2  LC|n 2008020038‏
996 ‎‡2  SUDOC|19188295X‏
996 ‎‡2  RERO|A011108745‏
996 ‎‡2  RERO|A022568544‏
996 ‎‡2  BIBSYS|4025693‏
996 ‎‡2  NTA|315548827‏
996 ‎‡2  DBC|87097961864644‏
996 ‎‡2  LC|nb2010026883‏
996 ‎‡2  BIBSYS|1592544498297‏
996 ‎‡2  NSK|000093105‏
996 ‎‡2  BLBNB|001574256‏
996 ‎‡2  ISNI|0000000394408105‏
996 ‎‡2  J9U|987007376397105171‏
996 ‎‡2  ISNI|0000000043232857‏
996 ‎‡2  LC|n 89605411‏
996 ‎‡2  SUDOC|113639481‏
996 ‎‡2  LC|no 97053865‏
996 ‎‡2  CAOONL|ncf10643911‏
996 ‎‡2  BNF|17142372‏
996 ‎‡2  J9U|987007269530505171‏
996 ‎‡2  LC|n 95041174‏
996 ‎‡2  NTA|160438004‏
996 ‎‡2  LC|no2009013249‏
996 ‎‡2  NKC|stk2007383196‏
996 ‎‡2  CAOONL|ncf10706951‏
996 ‎‡2  DNB|136030734‏
996 ‎‡2  SUDOC|16975023X‏
996 ‎‡2  BNE|XX1218703‏
996 ‎‡2  NII|DA18724394‏
996 ‎‡2  NTA|29748897X‏
996 ‎‡2  LC|no2003047800‏
996 ‎‡2  ISNI|0000000054789773‏
996 ‎‡2  LC|no 98079363‏
996 ‎‡2  ISNI|0000000401925144‏
996 ‎‡2  BIBSYS|90898503‏
996 ‎‡2  BNF|15004020‏
996 ‎‡2  LC|no2017111007‏
996 ‎‡2  BIBSYS|14006639‏
996 ‎‡2  LC|n 92043333‏
996 ‎‡2  BNF|16775415‏
996 ‎‡2  SIMACOB|269465699‏
996 ‎‡2  BNF|12093191‏
996 ‎‡2  BIBSYS|1022102‏
996 ‎‡2  ISNI|0000000051309818‏
996 ‎‡2  DNB|1041836074‏
996 ‎‡2  ISNI|0000000133567095‏
996 ‎‡2  NUKAT|n 2017076429‏
996 ‎‡2  J9U|987007430259805171‏
996 ‎‡2  LC|no2024096105‏
996 ‎‡2  BIBSYS|1707990462809‏
996 ‎‡2  RERO|A027655582‏
996 ‎‡2  LC|no 89012112‏
996 ‎‡2  BNF|18174793‏
996 ‎‡2  NSK|000667105‏
996 ‎‡2  LC|nb2014003939‏
996 ‎‡2  DNB|14263168X‏
996 ‎‡2  DNB|1122069405‏
996 ‎‡2  LC|nb2006021595‏
996 ‎‡2  BIBSYS|14016693‏
996 ‎‡2  LC|nb2013017681‏
996 ‎‡2  BIBSYS|3030556‏
996 ‎‡2  LC|n 2012074913‏
996 ‎‡2  CAOONL|ncf12120847‏
996 ‎‡2  SUDOC|167412876‏
996 ‎‡2  BIBSYS|1542227323818‏
996 ‎‡2  J9U|987007414680405171‏
996 ‎‡2  DNB|1079912088‏
996 ‎‡2  JPG|500271122‏
996 ‎‡2  BIBSYS|90524019‏
996 ‎‡2  ISNI|0000000402660213‏
996 ‎‡2  NTA|41110859X‏
996 ‎‡2  LC|nb2005015990‏
996 ‎‡2  LC|no2024037172‏
996 ‎‡2  LC|n 87878884‏
996 ‎‡2  NKC|jn20000605116‏
996 ‎‡2  ISNI|0000000463376232‏
996 ‎‡2  ISNI|0000000038197540‏
996 ‎‡2  DNB|1138949566‏
996 ‎‡2  LC|n 78078704‏
996 ‎‡2  LC|no2005009091‏
996 ‎‡2  DNB|1193435943‏
996 ‎‡2  LC|nb2002017659‏
996 ‎‡2  BIBSYS|2122154‏
996 ‎‡2  ISNI|0000000116623278‏
996 ‎‡2  ERRR|12520469‏
996 ‎‡2  NUKAT|n 2015094179‏
996 ‎‡2  SUDOC|227531825‏
996 ‎‡2  ISNI|0000000039853773‏
996 ‎‡2  J9U|987007384411405171‏
996 ‎‡2  ISNI|0000000043735083‏
996 ‎‡2  J9U|987007586337205171‏
996 ‎‡2  NUKAT|n 2007117996‏
996 ‎‡2  ISNI|0000000036897412‏
996 ‎‡2  NTA|21580919X‏
996 ‎‡2  ISNI|0000000116310773‏
996 ‎‡2  B2Q|0000034483‏
996 ‎‡2  BNE|XX888583‏
996 ‎‡2  NII|DA06032702‏
996 ‎‡2  DNB|1120543150‏
996 ‎‡2  NUKAT|n 2012168454‏
996 ‎‡2  BNF|17148758‏
996 ‎‡2  NII|DA13164598‏
996 ‎‡2  RERO|A027632046‏
996 ‎‡2  LC|no2024114668‏
996 ‎‡2  LC|n 96803486‏
996 ‎‡2  ISNI|0000000054262760‏
996 ‎‡2  CAOONL|ncf10376058‏
996 ‎‡2  LC|n 89225316‏
996 ‎‡2  BAV|495_124406‏
996 ‎‡2  J9U|987007270085005171‏
996 ‎‡2  ISNI|0000000074369362‏
996 ‎‡2  ISNI|0000000073606629‏
996 ‎‡2  LC|nb2015014459‏
996 ‎‡2  SUDOC|169842568‏
996 ‎‡2  NKC|xx0249012‏
996 ‎‡2  LC|n 90628354‏
996 ‎‡2  LC|no2013142611‏
996 ‎‡2  LC|n 2012035307‏
996 ‎‡2  DNB|1067414789‏
996 ‎‡2  NTA|134225074‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏